Benitec Biopharma
Benitec Biopharma
BNTC
NASDAQ
14.51
USD
0.14%
About
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration.
The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 15.8K |
| Three Month Average Volume | 646.1K |
| High Low | |
| Fifty-Two Week High | 10.88 USD |
| Fifty-Two Week Low | 2.69 USD |
| Fifty-Two Week High Date | 17 Jul 2024 |
| Fifty-Two Week Low Date | 18 Jan 2024 |
| Price and Volume | |
| Current Price | 9.245 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 9.25% |
| Thirteen Week Relative Price Change | 12.91% |
| Twenty-Six Week Relative Price Change | 49.61% |
| Fifty-Two Week Relative Price Change | 150.10% |
| Year-to-Date Relative Price Change | 141.70% |
| Price Change | |
| One Day Price Change | 2.15% |
| Thirteen Week Price Change | 20.85% |
| Twenty-Six Week Price Change | 64.50% |
| Five Day Price Change | 2.15% |
| Fifty-Two Week Price Change | 213.39% |
| Year-to-Date Price Change | 186.22% |
| Month-to-Date Price Change | 7.25% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.12273 USD |
| Book Value Per Share (Most Recent Quarter) | 4.22051 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.12273 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.22051 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -9.52115 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.05412 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00311 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -14.11585 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -9.8678 USD |
| Normalized (Last Fiscal Year) | -14.11585 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -14.11585 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -9.8678 USD |
| Including Extraordinary Items (Last Fiscal Year) | -14.11585 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -9.8678 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.50491 USD |
| Cash Per Share (Most Recent Quarter) | 5.19049 USD |
| Cash Flow Per Share (Last Fiscal Year) | -14.01769 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -9.61009 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -8.98528 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -417 |
| Cash Flow Revenue (Trailing Twelve Months) | -288,643 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -309,885.70% |
| Pretax Margin (Last Fiscal Year) | -26,082.67% |
| Pretax Margin (5 Year) | -468.04% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 100.00% |
| Gross Margin (Trailing Twelve Months) | 1,542.86% |
| Gross Margin (5 Year) | 96.86% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -25,441.33% |
| Operating Margin (Trailing Twelve Months) | -307,028.60% |
| Operating Margin (5 Year) | -464.38% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -26,082.67% |
| Net Profit Margin (Trailing Twelve Months) | -309,885.70% |
| Net Profit Margin (5 Year) | -468.04% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -33.13% |
| Tangible Book Value (5 Year) | -57.08% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -53.84% |
| Revenue Change (Trailing Twelve Months) | -89.71% |
| Revenue Per Share Growth | -34.05% |
| Revenue Growth (5 Year) | -9.74% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -56.51% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 38.78% |
| EPS Change (Trailing Twelve Months) | 59.77% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 462 |
| Price to Tangible Book (Most Recent Quarter) | 8 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -14,143,000 |
| Net Debt (Last Fiscal Year) | -2,477,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1.2K |
| Price to Sales (Trailing Twelve Months) | 13.3K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 75 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -18,013,000 |
| Free Cash Flow (Trailing Twelve Months) | -20,205,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -42 |
| Net Interest Coverage (Trailing Twelve Months) | -307 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -374.86% |
| Return on Assets (Trailing Twelve Months) | -186.85% |
| Return on Assets (5 Year) | -83.43% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -1,268.61% |
| Return on Equity (Trailing Twelve Months) | -267.59% |
| Return on Equity (5 Year) | -100.39% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -996.28% |
| Return on Investment (Trailing Twelve Months) | -260.89% |
| Return on Investment (5 Year) | -98.77% |